Europe Brain Cancer Diagnostics Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, and Others); Cancer Type (Acoustic Neuroma, Astrocytoma, Craniopharyngiomas, Ganglioneuromas, Glioblastoma Multiforme, Meningiomas, Ependymomas, and Others); End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others)


No. of Pages: 161    |    Report Code: TIPRE00025898    |    Category: Life Sciences

Europe Brain Cancer Diagnostics Market
Buy Now

Market Introduction

Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body.  Brain tumors are categorized into 40 major types that are further classified into two major groups, including benign, i.e., slow-growing and have less possibility to spread, and malignant, i.e., cancerous, and more likely to spread.

Thus, the increase in prevalence of brain cancer is expected to create a significant demand for brain cancer diagnostics in the coming years, which is further anticipated to drive the brain cancer diagnostics market.

Patients with cancer have been negatively impacted during the COVID-19 pandemic, as many of these individuals may be immunosuppressed and of older age. Additionally, cancer follow-up or imaging appointments have been delayed in many clinics around the world. Postponement of routine screening examinations will result in delays in new cancer diagnoses. Clinics are continuing to monitor and adapt their appointment schedules based on local outbreaks of COVID-19. Studies on COVID-19 in patients with cancer are limited, but consistently indicate that this population is at risk for more severe COVID-19 illness. Data from recent studies also suggest that pediatric patients with cancer have a lower risk of severe COVID-19 illness compared with adults. Certain features of SARS-CoV-2 infection detected by lung, brain, and gastrointestinal imaging may confound radiologists’ interpretation of cancer diagnosis, staging, and treatment response. Lastly, as clinics begin to reopen for routine appointments, protocols have been put in place to reduce SARS-CoV-2 exposure to patients during their visits. This review details different perspectives on the impact of the COVID-19 pandemic on patients with cancer and on cancer imaging.

 


Get more information on this report

Europe Brain Cancer Diagnostics Strategic Insights

Strategic insights for the Europe Brain Cancer Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/europe-brain-cancer-diagnostics-market-strategic-framework.webp
Get more information on this report

Europe Brain Cancer Diagnostics Report Scope

Report Attribute Details
Market size in 2021 US$ 207.5 Million
Market Size by 2028 US$ 601.0 Million
Global CAGR (2021 - 2028) 16.4%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Diagnostic Type
  • Imaging Test
  • Lumbar Puncture
  • Biopsy
  • Molecular Testing
By Cancer Type
  • Acoustic Neuroma
  • Astrocytoma
  • Craniopharyngiomas
  • Ganglioneuromas
  • Glioblastoma Multiforme
  • Meningiomas
  • Ependymomas
By End User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
Regions and Countries Covered Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Market leaders and key company profiles
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers A
  • GE Healthcare
  • Biocept, Inc.
  • Koninklijke Philips N.V
  • Canon Medical Systems
  • Hitachi, Ltd.
  • Neusoft Medical Systems
  • Get more information on this report

    Europe Brain Cancer Diagnostics Regional Insights

    The geographic scope of the Europe Brain Cancer Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/europe-brain-cancer-diagnostics-market-geography.webp
    Get more information on this report


    Market Overview and Dynamics

    The Brain cancer diagnostics market in Europe is expected to grow from US$ 207.5 million in 2021 to US$ 601.0 million by 2028; it is estimated to grow at a CAGR of 16.4% from 2021 to 2028. Artificial intelligence involves the use of powerful computers to perform tasks usually associated with human intelligence. A type of artificial intelligence called deep learning uses complex mathematical algorithms (sometimes called convolutional neural networks) to extract features from data and then "train" them. This training enables the algorithm to recognize patterns and perform tasks such as analysing images. To combine the powerful functions of the SRH imager with AI, the researchers began to perform algorithm training on the brain tumor tissue images produced by the SRH. The researchers pointed out that the ability of artificial intelligence technology and pathologists to verify each other highlights the need for pathologists to cooperate with artificial intelligence technology to interpret challenging cases and ensure the highest possible diagnostic accuracy. Both SRH and AI imaging are emerging technologies, so integrating them into healthcare will be challenging. AI technology enables surgeons to identify areas containing tumors or healthy tissue speedily and precisely. Thus, SRH?artificial intelligence is being increasingly used to enhance brain tumor diagnosis during surgery.    

     

    Key Market Segments

    In terms of diagnostic type, the imaging test segment accounted for the largest share of the Europe brain cancer diagnostics market in 2020. In terms of cancer type, the glioblastoma multiforme segment accounted for the largest share of the Europe brain cancer diagnostics market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the Europe brain cancer diagnostics market in 2020.

     

    Major Sources and Companies Listed

    A few major primary and secondary sources referred to for preparing this report on the brain cancer diagnostics market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Thermo Fisher Scientific Inc., Siemens Healthineers A, GE Healthcare, Biocept, Inc., Koninklijke Philips N.V, Canon Medical Systems, Hitachi, Ltd., and Neusoft Medical Systems.

     

    Reasons to buy report

    • To understand the Europe Brain cancer diagnostics market landscape and identify market segments that are most likely to guarantee a strong return
    • Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe Brain cancer diagnostics market
    • Efficiently plan M&A and partnership deals in Europe Brain cancer diagnostics market by identifying market segments with the most promising probable sales
    • Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe Brain cancer diagnostics market
    • Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.

     

    Europe Brain Cancer Diagnostics Market Segmentation

     

    By Diagnostic Type

    • Imaging Test
      • MRI
      • CT Scan
      • PET
    • Biopsy
    • Molecular Testing
    • Lumbar Puncture
    • Others

     

    By Cancer Type

    • Glioblastoma Multiforme
    • Astrocytomas
    • Ependymomas
    • Others

     

    By End User

    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Others

     

    By Country

    • Europe
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Rest of Europe

     

    Companies Mentioned

    1. Thermo Fisher Scientific Inc.
    2. Siemens Healthineers A
    3. GE Healthcare
    4. Biocept, Inc.
    5. Koninklijke Philips N.V
    6. Canon Medical Systems
    7. Hitachi, Ltd.
    8. Neusoft Medical Systems

     

     

     

    The List of Companies - Europe Brain Cancer Diagnostics Market

    1. Thermo Fisher Scientific Inc.
    2. Siemens Healthineers A
    3. GE Healthcare
    4. Biocept, Inc.
    5. Koninklijke Philips N.V
    6. Canon Medical Systems
    7. Hitachi, Ltd.
    8. Neusoft Medical Systems
    Frequently Asked Questions
    How big is the Europe Brain Cancer Diagnostics Market?

    The Europe Brain Cancer Diagnostics Market is valued at US$ 207.5 Million in 2021, it is projected to reach US$ 601.0 Million by 2028.

    What is the CAGR for Europe Brain Cancer Diagnostics Market by (2021 - 2028)?

    As per our report Europe Brain Cancer Diagnostics Market, the market size is valued at US$ 207.5 Million in 2021, projecting it to reach US$ 601.0 Million by 2028. This translates to a CAGR of approximately 16.4% during the forecast period.

    What segments are covered in this report?

    The Europe Brain Cancer Diagnostics Market report typically cover these key segments-

    • Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing)
    • Cancer Type (Acoustic Neuroma, Astrocytoma, Craniopharyngiomas, Ganglioneuromas, Glioblastoma Multiforme, Meningiomas, Ependymomas)
    • End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers)

    What is the historic period, base year, and forecast period taken for Europe Brain Cancer Diagnostics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Brain Cancer Diagnostics Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Europe Brain Cancer Diagnostics Market?

    The Europe Brain Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers A
  • GE Healthcare
  • Biocept, Inc.
  • Koninklijke Philips N.V
  • Canon Medical Systems
  • Hitachi, Ltd.
  • Neusoft Medical Systems
  • Who should buy this report?

    The Europe Brain Cancer Diagnostics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Brain Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now